{"nctId":"NCT03760068","briefTitle":"Mylan Insulin Aspart Study","startDateStruct":{"date":"2018-11-07","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 1"],"count":478,"armGroups":[{"label":"MYL-1601D Product (100 U/mL)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: MYL-1601D Product"]},{"label":"FlexPen NovoLog® (100 U/mL)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: FlexPen NovoLog®"]}],"interventions":[{"name":"MYL-1601D Product","otherNames":[]},{"name":"FlexPen NovoLog®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n1. Written and signed informed consent.\n2. Clinical diagnosis of type 1 diabetes mellitus for at least 6 months prior to screening.\n3. Subject is able and willing to comply with the requirements of the study protocol.\n\nExclusion Criteria\n\n1. History or presence of a medical condition or disease that in the Investigator's opinion would place the subject at an unacceptable risk from study participation.\n2. History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the study, OR history of significant allergic drug reactions.\n3. Any clinically significant abnormality in electrocardiogram or safety laboratory tests.\n4. Any elective surgery requiring hospitalization planned during the study period.\n5. History of a significant medical condition, such as unstable angina, myocardial infarction, stroke or transient ischemic attack in the 6 months before screening.\n6. Subjects with major depressive illness in the last 3 years.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Emergent Antibody Response (TEAR)","description":"The number of subjects who were TEAR positive.\n\nTEAR is defined as either one of the following:\n\n1. Subjects who are Anti-Drug Antibody (ADA) negative at baseline and become positive at any timepoint post baseline\n2. Subjects who are ADA positive at baseline and demonstrate 4-fold increase in titer values at any timepoint post baseline visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline","description":"Mean (SD) change from baseline HbA1c at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.735"},{"groupId":"OG001","value":"0.04","spread":"0.723"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose From Baseline","description":"Mean (SD) change from baseline plasma glucose at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.400","spread":"5.8162"},{"groupId":"OG001","value":"0.599","spread":"5.1553"}]}]}]},{"type":"SECONDARY","title":"Change in Prandial Insulin Dose From Baseline","description":"Mean (SD) change from baseline daily mealtime insulin dose at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0079","spread":"0.14608"},{"groupId":"OG001","value":"-0.0008","spread":"0.09731"}]}]}]},{"type":"SECONDARY","title":"Change in Basal Insulin Dose From Baseline","description":"Mean (SD) change from baseline total daily insulin dose at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0053","spread":"0.06459"},{"groupId":"OG001","value":"0.0001","spread":"0.05152"}]}]}]},{"type":"SECONDARY","title":"Change in Total Daily Insulin Dose From Baseline","description":"Mean (SD) change from baseline total daily insulin dose at Week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0178","spread":"0.15888"},{"groupId":"OG001","value":"0.0024","spread":"0.10649"}]}]}]},{"type":"SECONDARY","title":"Change in 7-point Self-monitored Blood Glucose (SMBG) Profile From Baseline","description":"Mean (SD) change in 7-point SMBG profile from baseline to Week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1180","spread":"2.09287"},{"groupId":"OG001","value":"0.0999","spread":"1.86471"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":238},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Urinary Tract Infection","Headache","Hypertension"]}}}